2. Metabolic Enzyme/Protease
  3. NADPH Oxidase
  4. VAS2870

VAS2870 is a NADPH oxidase (NOX) inhibitor.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 722456-31-7

Tamaño Precio Stock Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 18 publication(s) in Google Scholar

Other Forms of VAS2870:

VAS2870 Related Antibodies

Top Publications Citing Use of Products

    VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867.  [Abstract]

    VAS2870 and MPO-IN-28 significantly reduced the ROS levels of dHL-60.5ab stain VAS2870 and MPO-IN-28 downregulated citH3 expression.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867.  [Abstract]

    VAS2870 and MPO-IN-28 eliminated NETosis.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867.  [Abstract]

    PBS, CC-lEVs, and VAS2870 were continuously injected into C57BL mice via the tail vein for 5 days. Six hours after completing the injections on the 5th day, an iliac vein constriction surgery was performed, followed by collection of plasma and thrombus tissues 48 h post-surgery.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867.  [Abstract]

    Knockout of cyba or use of VAS2870 (2.5 mg/kg, iv, 5 days) markedly inhibited NETosis. H&E staining and confocal microscopy to assess the formation of thrombus and NETosis in the iliac vein across different treatment groups.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 21:e07867.  [Abstract]

    Knockout of cyba or use of VAS2870 (2.5 mg/kg, iv, 5 days) markedly inhibited VTE. Quantification of thrombus area based on H&E staining among various treatment groups.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 Apr 9;524(3):575-581.  [Abstract]

    VAS2870 protects against LPS-induced cell injury through inhibiting Nox2 expression in A549 cells. The expression of Nox2 in control, LPS (150 mg/ml), VAS þ LPS (preincubating cells with 10 mM VAS2870 followed by 150 mg/ml LPS intervention) and VAS (10 mM VAS2870) groups is determined by western blot.

    VAS2870 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2020 Apr 9;524(3):575-581.  [Abstract]

    VAS2870 protects against LPS-induced cell injury through inhibiting Nox2 expression in A549 cells. The expression of Nox2 in control, LPS (150 mg/ml), VAS þ LPS (preincubating cells with 10 mM VAS2870 followed by 150 mg/ml LPS intervention) and VAS (10 mM VAS2870) groups is determined by immunofluorescence labeling (E).

    Ver todos los productos específicos de isoformas NADPH Oxidase:

    Ver todas las isoformas
    NOX1 NOX2 NOX4 NOX5 DUOX1

    • Actividad biológica

    • Protocolo

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    VAS2870 is a NADPH oxidase (NOX) inhibitor.

    IC50 & Target

    Target: NADPH oxidase[1]
    In Vitro

    VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequent production of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, but not DNA synthesis. Preincubation with VAS2870 (10 and 20 μM) completely abolishes PDGF-mediated NADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20 μM) does not affect PDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in a concentration-dependent manner (100% inhibition at 10 μM)[1]. VAS2870 inhibits dose-dependently autocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS production and thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rat hepatoma cells. VAS2870 inhibits proliferation of different human hepatocellular carcinoma (HCC) cell lines. VAS2870 pretreatment enhances TGF-b-mediated apoptosis of FaO rat hepatoma cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    VAS2870 Related Antibodies
    Peso molecular

    360.39

    Fòrmula

    C18H12N6OS
    No. CAS
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C1(N(CC2=CC=CC=C2)N=N3)=C3C(SC4=NC5=C(C=CC=C5)O4)=NC=N1
    Envío

    Room temperature in continental US; may vary elsewhere.
    Almacenamiento
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvente y solubilidad
    In Vitro: 

    DMSO : 83.3 mg/mL (231.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7748 mL 13.8739 mL 27.7477 mL
    5 mM 0.5550 mL 2.7748 mL 5.5495 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Calculadora de molaridad

    • Calculadora de dilución

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureza y Documentación
    Referencias
    Ensayo de quinasas
    [1]

    NADPH oxidase activity is measured by lucigenin-enhanced chemiluminescence in a 50 mM phosphate buffer (buffer A), pH 7.0, containing 1 mM EGTA, protease inhibitors, 150 mM sucrose, 5 μM lucigenin, and 250 μM NADPH as substrate. Quiescent cells are starved by serum deprivation for 24 h and treated as indicated, ished twice with ice-cold phosphate buffered saline (PBS), pH 7.4, and harvested. After low spin centrifugation, the pellet is re-suspended in ice-cold buffer A, lacking lucigenin and substrate. Then, the cells are lysed and total protein concentration is determined using a Bradford assay and adjusted to 1 mg/mL. 100 μL aliquots of the protein sample are measured over 6 min in quadruplicates using NADPH (100 μM) as substrate in a scintillation counter. Data are collected at 2 min intervals in order to measure relative changes in NADPH oxidase activity[1].

    MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
    Ensayo celular
    [2]

    To test autocrine growth, cells are serum deprived at 40% confluence and, when indicated, the NADPH oxidase inhibitors Apocynin (300 mM) or VAS2870 are added 30 min before serum deprivation and maintained along the experiment. For TGF-b experiments, cells at 70% confluence are serum deprived for 16 h and treated with 2 ng/mL TGF-β in the presence or absence of the EGFR inhibitor AG1478 (20 mM) or VAS2870 (25 mM), which are added 30 min prior to TGF-β[2].

    MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
    Referencias

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.7748 mL 13.8739 mL 27.7477 mL 69.3693 mL
    5 mM 0.5550 mL 2.7748 mL 5.5495 mL 13.8739 mL
    10 mM 0.2775 mL 1.3874 mL 2.7748 mL 6.9369 mL
    15 mM 0.1850 mL 0.9249 mL 1.8498 mL 4.6246 mL
    20 mM 0.1387 mL 0.6937 mL 1.3874 mL 3.4685 mL
    25 mM 0.1110 mL 0.5550 mL 1.1099 mL 2.7748 mL
    30 mM 0.0925 mL 0.4625 mL 0.9249 mL 2.3123 mL
    40 mM 0.0694 mL 0.3468 mL 0.6937 mL 1.7342 mL
    50 mM 0.0555 mL 0.2775 mL 0.5550 mL 1.3874 mL
    60 mM 0.0462 mL 0.2312 mL 0.4625 mL 1.1562 mL
    80 mM 0.0347 mL 0.1734 mL 0.3468 mL 0.8671 mL
    100 mM 0.0277 mL 0.1387 mL 0.2775 mL 0.6937 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    VAS2870 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    VAS2870722456-31-7VAS 2870VAS-2870NADPH OxidaseNOXInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    VAS2870
    Cat. No.:
    HY-12804
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB) Italian - IT (392 KB) Korean - KR (392 KB) Portuguese - PT (392 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.